Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66
            ®
            cell culture platform

Masafumi Endo; Mitsuyoshi Tanishima; Kayo Ibaragi; Kenshi Hayashida; Tadashi Fukuda; Tetsuro Tanabe; Takeshi Naruse; Yoichiro Kino; Kohji Ueda

doi:10.1111/irv.12755

Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66 ® cell culture platform

Influenza and Other Respiratory Viruses ◽

10.1111/irv.12755 ◽

2020 ◽

Vol 14 (5) ◽

pp. 551-563

Author(s):

Masafumi Endo ◽

Mitsuyoshi Tanishima ◽

Kayo Ibaragi ◽

Kenshi Hayashida ◽

Tadashi Fukuda ◽

...

Keyword(s):

Cell Culture ◽

Influenza Vaccine ◽

Phase Ii ◽

Clinical Phase ◽

H5n1 Influenza ◽

Phase Ii And Iii

Download Full-text

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults

BMC Infectious Diseases ◽

10.1186/1471-2334-10-338 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 10

Author(s):

Hideaki Nagai ◽

Hideyuki Ikematsu ◽

Kazuyoshi Tenjinbaru ◽

Atsushi Maeda ◽

Mamadou Dramé ◽

...

Keyword(s):

Influenza Vaccine ◽

Multicentre Study ◽

Phase Ii ◽

Open Label ◽

H5n1 Influenza ◽

Japanese Adults

Download Full-text

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

Vaccine ◽

10.1016/j.vaccine.2009.10.019 ◽

2010 ◽

Vol 28 (3) ◽

pp. 840-848 ◽

Cited By ~ 56

Author(s):

Wendy Keitel ◽

Nicola Groth ◽

Maria Lattanzi ◽

Michaela Praus ◽

Anne Katrin Hilbert ◽

...

Keyword(s):

Clinical Trial ◽

Cell Culture ◽

Influenza Vaccine ◽

Phase 1 ◽

Vaccine Safety ◽

H5n1 Influenza ◽

A Cell ◽

Dose Ranging

Download Full-text

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming

Vaccine ◽

10.1016/j.vaccine.2012.07.077 ◽

2012 ◽

Vol 30 (43) ◽

pp. 6127-6135 ◽

Cited By ~ 21

Author(s):

Maikel V.W. van der Velden ◽

Gerald Aichinger ◽

Eva Maria Pöllabauer ◽

Alexandra Löw-Baselli ◽

Sandor Fritsch ◽

...

Keyword(s):

Cell Culture ◽

Immune Response ◽

Single Dose ◽

Influenza Vaccine ◽

Vero Cell ◽

H5n1 Influenza ◽

Memory Immune Response

Download Full-text

Peripheral and penile angiography with iotrolan 280 versus non-ionic monomers: results of the European clinical phase II and III trials

European Radiology ◽

10.1007/bf02343258 ◽

1995 ◽

Vol 5 (S2) ◽

pp. S30-S38 ◽

Cited By ~ 2

Author(s):

J. K. Gmeinwieser ◽

B. -I. Wenzel-Hora

Keyword(s):

Phase Ii ◽

Clinical Phase ◽

Phase Ii And Iii

Download Full-text

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial

Vaccine ◽

10.1016/j.vaccine.2008.11.003 ◽

2009 ◽

Vol 27 (5) ◽

pp. 786-791 ◽

Cited By ~ 35

Author(s):

N. Groth ◽

E. Montomoli ◽

C. Gentile ◽

I. Manini ◽

R. Bugarini ◽

...

Keyword(s):

Clinical Trial ◽

Cell Culture ◽

Influenza Vaccine ◽

Phase I ◽

Mammalian Cell ◽

Phase Ii ◽

Mammalian Cell Culture ◽

Phase Ii Clinical Trial ◽

Sequential Phase

Download Full-text

Human medicines European public assessment report (EPAR): Vepacel, Prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 17/02/2012, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-962c3e ◽

2019 ◽

Author(s):

Keyword(s):

Cell Culture ◽

Influenza Vaccine ◽

Disease Outbreaks ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

Case Medical Research ◽

10.31525/ct1-nct03893669 ◽

2019 ◽

Author(s):

Keyword(s):

Cell Culture ◽

Influenza Vaccine ◽

Healthy Adults

Download Full-text

Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial

Vaccine ◽

10.1016/j.vaccine.2021.02.014 ◽

2021 ◽

Author(s):

Lee-Jah Chang ◽

Evan J. Anderson ◽

Robert Jeanfreau ◽

Ying He ◽

Bryony Hicks ◽

...

Keyword(s):

Influenza Vaccine ◽

Phase Ii ◽

Dose Finding ◽

Randomized Controlled ◽

High Doses ◽

Quadrivalent Influenza Vaccine

Download Full-text

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease

Ophthalmology ◽

10.1016/j.ophtha.2019.01.024 ◽

2019 ◽

Vol 126 (6) ◽

pp. 792-800 ◽

Cited By ~ 7

Author(s):

David L. Wirta ◽

Gail L. Torkildsen ◽

Helen R. Moreira ◽

John D. Lonsdale ◽

Joseph B. Ciolino ◽

...

Keyword(s):

Phase Ii ◽

Dry Eye ◽

Phase Ii Study ◽

Dry Eye Disease ◽

Eye Disease ◽

Clinical Phase

Download Full-text

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

Supportive Care in Cancer ◽

10.1007/s00520-012-1384-0 ◽

2012 ◽

Vol 20 (11) ◽

pp. 2661-2668 ◽

Cited By ~ 19

Author(s):

Linda T. Vahdat ◽

Eva S. Thomas ◽

Henri H. Roché ◽

Gabriel N. Hortobagyi ◽

Joseph A. Sparano ◽

...

Keyword(s):

Clinical Trials ◽

Peripheral Neuropathy ◽

Phase Ii ◽

Phase Ii And Iii

Download Full-text

Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66 ® cell culture platform

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming

Peripheral and penile angiography with iotrolan 280 versus non-ionic monomers: results of the European clinical phase II and III trials

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial

Human medicines European public assessment report (EPAR): Vepacel, Prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 17/02/2012, Revision: 9, Status: Authorised

Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial